Home 2018-07-05T11:36:59+00:00

for a Brighter Tomorrow

JOIN MAILING LIST

PRESENTATION

PIPELINE

INVESTORS

ABOUT US

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed an innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, has the potential to better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles.

Oramed’s oral insulin is currently in advanced clinical trials under the US FDA for both type 1 and type 2 diabetes.

In addition to oral insulin, the company’s proprietary POD™ technology can be used to orally administer a number of protein-based therapies, which are available only via injection.

PRESS RELEASES

Oramed Appoints Dr. Arie Mayer to Board of Directors

December 5th, 2019|Comments Off on Oramed Appoints Dr. Arie Mayer to Board of Directors

Dr. Mayer is the current Managing Director and Chairman of the [...]

Oramed to Present a Scientific Poster at International Diabetes Federation Congress

December 2nd, 2019|Comments Off on Oramed to Present a Scientific Poster at International Diabetes Federation Congress

NEW YORK, December 2, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: [...]